# US 2021/0275494 A1 · Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275494 A1
- Document ID: US20210275494A1
- Status: Published application
- Kind: A1
- Application number: 17/261,279
- Filed: 2019-07-16
- Published: 2021-09-09
- Earliest claimed: 2018-07-16
- Assignees: The Regents of the University of Colorado
- Applicants: Regents of the University of Colorado, A Body Corporate
- Inventors: Richard J. JOHNSON; Miguel A. LANASPA-GARCIA; Sondra BLAND
- Web page: https://patentgrep.com/patent/US20210275494A1

## CPC

- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 36/00: Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K39/36)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 25/32: Alcohol-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of one or more fructokinase (ketohexokinase) (KHK) inhibitors to both prevent and treat a wide variety of diseases including, but not limited to, alcohol craving, alcohol addiction, alcohol induced liver disease including fatty liver and cirrhosis.

## Claims

### Claim 1

A method of reducing a craving for alcohol in a subject, comprising:
administering a therapeutically effective amount of a ketohexokinase (KHK) inhibitor to the subject to inhibit KHK activity in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the KHK inhibitor comprises a small molecule; a ribozyme, an interfering molecule, a peptide, or an antibody targeted to KHK, or a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the KHK inhibitor comprises an interfering molecule.

### Claim 4 (depends on 3)

The method of claim 3, wherein the interfering molecule comprises a phosphothioate morpholino oligomer (PMO), miRNA, siRNA, methylated siRNA, treated-siRNA, shRNA, antisense RNA, or a dicer-substrate 27-mer duplex.

### Claim 5 (depends on 1)

The method of claim 1, wherein the KHK inhibitor comprises a plant extract from one or more plants and an acceptable carrier.

### Claim 6 (depends on 5)

The method of claim 5, wherein the plant extract is obtained from a genus selected from the group consisting of Angelica, Cratoxylum, Myrica, Psoralea, Scutellaria, Diospyros, Andrographis, Nymphaea, Chloroxylon, Petroselinum, Morus, Pteris, Garcinia, and Malus, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitor comprises a small molecule KHK inhibitor.

### Claim 8

A method of treating an alcoholism in a subject in need thereof, comprising:
administering to the subject a therapeutically effective amount of a ketohexokinase (KHK) inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the KHK inhibitor comprises a small molecule, an interfering molecule, a peptide, a plant-based extract or an antibody targeted to KHK, or a combination of any of the foregoing.

### Claim 10

A method of treating an alcohol-induced liver disease in a subject, comprising:
administering to the subject a composition comprising a therapeutically effective amount of a KHK inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition comprises a therapeutically effective amount of a KHK inhibitor and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 10)

The method of claim 10, wherein the KHK inhibitor comprises a small molecule, an interfering molecule, a peptide, a plant-based extract or an antibody targeted to KHK, or a combination of any of the foregoing.

### Claim 13 (depends on 10)

The method of claim 10, wherein the liver disease comprises a fatty liver.

### Claim 14 (depends on 10)

The method of claim 10, wherein the liver disease comprises steatohepatitis.

### Claim 15 (depends on 10)

The method of claim 10, wherein the liver disease comprises cirrhosis.

### Claim 16 (depends on 10)

The method of claim 10, wherein the liver disease is acute alcoholic hepatitis.

### Claim 17

A method of treating alcohol-induced pancreatitis in a subject, the method comprising:
administering a therapeutically effective amount of a ketohexokinase (KHK) inhibitor to the subject to inhibit KHK activity in the subject.

### Claim 18

A method of preventing alcoholism, an alcohol-induced liver disease, or alcohol-induced pancreatitis in a subject or recurrence of the same, the method comprising:
administering a therapeutically effective amount of a ketohexokinase (KHK) inhibitor to the subject to inhibit KHK activity in the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject has been diagnosed with an alcohol-induced liver disease or alcohol-induced pancreatitis.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method according to any of claims 1-19, further comprising co-administering a conjunctive agent.

### Claim 21 (depends on 20)

The method of claim 20, wherein the conjunctive agent comprises one or more of aldose reductase agents, uric acid lowering agents, corticosteroid (e.g. prednisone), pentoxifylline, steroid derivatives, naltrexone, acamprosate, baclofen, disulfiram, Antabuse, campral, or lioresal, or a combination thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the uric acid lowering agent is a xanthine oxidase inhibitor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the xanthine oxidase inhibitor is allopurinol, oxypurinol, or febuxostat, or a combination thereof.

### Claim 24 (depends on 21)

The method of claim 21, wherein the aldose reductase agents is sorbanil, zopolrestat, ponalrestat, or toirestat, or a combination thereof.

### Claim 25 (depends on 21)

The method of claim 21, wherein the conjunctive agent comprises naltrexone, acamprosate, baclofen, disulfiram, Antabuse, campral, or lioresal, or a combination thereof.
